Most people, when requested to consider schizophrenia, take into consideration constructive signs, like hallucinations and delusions. Gustavo Alva, MD, DFAPA, encourages us to assume past these constructive hallmarks of schizophrenia.
Damaging signs of schizophrenia, like asociality, alogia, and blunted have an effect on, finally stymie the best way people talk and socialize. Extra symptomatology, resembling cognitive signs, excitability, and irritability, drastically have an effect on a affected person’s day-to-day life. That’s the reason we’d like totally different medicines to handle totally different domains, shared Alva.
“It’s good having medicines that don’t simply tackle 1 core drawback, however even have a pleasant impact throughout totally different domains,” shared Alva.
These medicines embrace Cobenfy (xanomeline and trospium chloride), the primary drug with a novel mechanism for schizophrenia in a long time. You possibly can hear extra from Alva about Cobenfy within the video, “Educating Sufferers About Cobenfy for the Therapy of Schizophrenia,” right here.
In case you are concerned with studying extra about cross-tapering onto Cobenfy, watch Alva’s different video, “A Scientific Problem: Transitioning Sufferers to Cobenfy,” right here.
Dr Alva is a board-certified psychiatrist, a paid marketing consultant of Otsuka America Pharmaceutical, Inc, and Lundbeck, and Temper Issues Part Editor for Psychiatric Occasions.
